Skip Page Header

Home > Methadone, Pierre Robin sequence and other congenital anomalies: case-control study.

Cleary, Brian and Loane, Maria and Addor, Marie-Claude and Barisic, Ingeborg and de Walle, Hermien EK and Matias Dias, Carlos and Gatt, Miriam and Klungsoyr, Kari and McDonnell, Bob and Neville, Amanda and Pierini, Anna and Rissmann, Anke and Tucker, David F and Zurriaga, Oscar and Dolk, Helen (2020) Methadone, Pierre Robin sequence and other congenital anomalies: case-control study. Archives of Disease in Childhood. Fetal and Neonatal edition , 105 , (2) , pp. 151-157.

OBJECTIVE
Methadone is a vital treatment for women with opioid use disorder in pregnancy. Previous reports suggested an association between methadone exposure and Pierre Robin sequence (PRS), a rare craniofacial anomaly. We assessed the association between gestational methadone exposure and PRS.

DESIGN/SETTING
This case-malformed control study used European Surveillance of Congenital Anomalies population-based registries in Ireland, the Netherlands, Italy, Switzerland, Croatia, Malta, Portugal, Germany, Wales, Norway and Spain, 1995-2011.

PATIENTS
Cases included PRS based on International Classification of Disease (ICD), Ninth Edition-British Paediatric Association (BPA) code 75 603 or ICD, Tenth Edition-BPA code Q8708. Malformed controls were all non-PRS anomalies, excluding genetic conditions, among live births, fetal deaths from 20 weeks' gestation and terminations of pregnancy for fetal anomalies. An exploratory analysis assessed the association between methadone exposure and other congenital anomalies (CAs) excluding PRS. Methadone exposure was ascertained from medical records and maternal interview.

RESULTS
Among 87 979 CA registrations, there were 127 methadone-exposed pregnancies and 336 PRS cases. There was an association between methadone exposure and PRS (OR adjusted for registry 12.3, 95% CI 5.7 to 26.8). In absolute terms, this association reflects a risk increase from approximately 1-12 cases per 10 000 births. A raised OR was found for cleft palate (adjusted OR 5.0, 95% CI 2.7 to 9.2).

CONCLUSIONS
These findings suggest that gestational methadone exposure is associated with PRS. The association may be explained by unmeasured confounding factors. The small increased risk of PRS in itself does not alter the risk-benefit balance for gestational methadone use. The association with cleft palate, a more common CA, should be assessed with independent data.


Click here to request a copy of this literature

Repository Staff Only: item control page